Veraxa Biotech Holding AG (NASDAQ:VRXA) Short Interest Down 46.3% in August

Veraxa Biotech Holding AG (NASDAQ:VRXA – Get Free Report) was the recipient of a large decrease in short interest in August. As of August 31st, there was short interest totaling 202,960 shares, a decrease of 46.3% from the August 15th total of 378,219 shares. Based on an average daily trading volume, of 204,024 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.6% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Veraxa Biotech from a “sell” rating to a “hold” rating in a research report on Monday, August 31st.

Get Veraxa Biotech alerts:

View Our Latest Stock Analysis on Veraxa Biotech

Insider Activity

In other Veraxa Biotech news, Director Oliver Rolf Baumann purchased 50,000 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was acquired at an average cost of $1.50 per share, with a total value of $75,000.00. Following the completion of the purchase, the director directly owned 5,773,618 shares in the company, valued at approximately $8,660,427. This represents a 0.87% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Veraxa Biotech Stock Performance

VRXA stock traded down $0.12 during mid-day trading on Tuesday, hitting $1.50. 33,983 shares of the company were exchanged, compared to its average volume of 558,830. Veraxa Biotech has a 1-year low of $1.27 and a 1-year high of $27.36.

Veraxa Biotech Company Profile

(Get Free Report)

Veraxa Biotech AG is a biotechnology company focused on developing targeted antibody-based medicines, with an emphasis on antibody-drug conjugates (ADCs). These therapies are designed to use antibodies to identify specific cells and deliver therapeutic agents more selectively.

The company’s work includes antibody discovery, therapeutic development and the design of ADC candidates that combine targeting antibodies with drug payloads. Its research is directed primarily toward potential treatments for cancer and other serious diseases, although specific development programs and product approvals may change as its pipeline advances.

Publicly available information about Veraxa Biotech’s corporate history, geographic operations and leadership is limited.

Featured Articles

• Five stocks we like better than Veraxa Biotech
• Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
• 3 Healthcare Stocks for 3 Stages of Life
• Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
• MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky

Receive News & Ratings for Veraxa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veraxa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.